Lot-to-lot variation of unfractionated heparin using the anti-factor Xa assay.

被引：0
|
作者：
Pullen, GE
Siegel, JE
Goodell, LA
机构：
[1] Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2002年 / 118卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
95
引用
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [31] Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors
    Stuart, Morgan
    Johnson, Linda
    Hanigan, Sarah
    Pipe, Steven W.
    Li, Shih-Hon
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1653 - 1660
  • [32] Study of two techniques for heparin therapy monitoring with an amidolytic anti-factor Xa assay
    Rosborough, TK
    Wolfson, PA
    LABORATORY MEDICINE, 2002, 33 (10) : 789 - 790
  • [33] Chemoenzymatic Synthesis of Heparin Oligosaccharides with both Anti-factor Xa and Anti-factor IIa Activities
    Xu, Yongmei
    Pempe, Elizabeth H.
    Liu, Jian
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (34) : 29054 - 29061
  • [34] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal
    Kitchen, S.
    Preston, F. E.
    Jennings, I.
    Kitchen, D. P.
    Woods, T. A. L.
    Walker, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2157 - 2158
  • [35] Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time
    Coons, James C.
    Iasella, Carlo J.
    Thornberg, Megan
    Fitzmaurice, Mary Grace
    Goehring, Kimberly
    Jablonski, Lindsay
    Leader, Dominic
    Meyer, Abby
    Seo, Hangil
    Benedict, Neal J.
    Smith, Roy E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (09) : 1015 - 1019
  • [36] Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol
    Williams-Norwood, Tanya
    Caswell, Megan
    Milner, Barbara
    Vescera, Joseph C.
    Prymicz, Kelly
    Ciszak, Amy G.
    Ingle, Carol
    Lacey, Christopher
    Stavrou, Evi X.
    AACN ADVANCED CRITICAL CARE, 2020, 31 (02) : 129 - 137
  • [37] Anti-factor Xa assay: An effective method to determine the appropriate dose of heparin in pregnant women
    Vineeta, Sharma
    Prakash, Choudbry Ved
    Renu, Saxena
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (01) : 118 - 119
  • [38] Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin
    Lehman, Christopher M.
    Rettmann, Jonathan A.
    Wilson, Lori W.
    Markewitz, Boaz A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (03) : 416 - 421
  • [39] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: reply to a rebuttal
    Cuker, A.
    Cines, D. B.
    Pollak, E. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2158 - 2159
  • [40] The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma - The need for using absolute anti-factor Xa and antithrombin activities
    Peyrou, V
    Beguin, S
    Boneu, B
    Hemker, HC
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (02) : 312 - 316
12345